1st Quarter - Report

ALKERMES, INC. for ALKERMES, INC.

Firm
Client
Income
—
Expenses
$1,170,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Maintain six protected classes for depressions and schizophrenia under Medicare Part D Drug pricing issues: HR3 - Lower Drug Costs Now Act; S2543 - Prescription Drug Pricing Reduction Act; H.R. 19 - Lower Costs, More Cures Act of 2019; Medicare Part D Restructuring;

LobbyistCovered position, as disclosed
ROBERT FORMAN —
MEGAN JACKSON —
PETER NORMAN —
KRISTI THOMPSON —

Contacted: Justice, Dept of (DOJ); Substance Abuse & Mental Health Services Administration (SAMHSA); Veterans Affairs, Dept of (VA); SENATE; Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Natl Drug Control Policy (NDCP); Natl Institutes of Health (NIH)

Bills named: H.R. 19 (116th), H.R. 3 (116th)

Alcohol and Drug Abuse ALC

Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings S.1983, CREATE Opportunities Act, H.R. 3496 CREATE Opportunities Act H.R. 1158, FY20 Consolidated Appropriations Act (PL-116-93) H.R. 1865, FY20 Further Consolidated Appropriations Act (PL 116-94)

LobbyistCovered position, as disclosed
ROBERT FORMAN —
MEGAN JACKSON —
PETER NORMAN —
KRISTI THOMPSON —

Contacted: Veterans Affairs, Dept of (VA); Executive Office of the President (EOP); Justice, Dept of (DOJ); Natl Institutes of Health (NIH); Substance Abuse & Mental Health Services Administration (SAMHSA); Health & Human Services, Dept of (HHS); SENATE; Office of Natl Drug Control Policy (NDCP); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1865 (116th), S. 1983 (116th), H.R. 3496 (116th), H.R. 1158 (116th)

Health Issues HCR

Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification SUPPORT for Patient and Communities Act (PL 115-271) Advance the use of and funding for medications to treat serious mental illness Legislation to promote treatment amongst incarcerated individuals with serious mental illness S.2690, Restoring, Enhancing, Securing, and Promoting Our Nation's Safety Efforts Act of 2019 S. 3312, HR 5909, Crisis Stabilization and Reentry Act;

LobbyistCovered position, as disclosed
ROBERT FORMAN —
MEGAN JACKSON —
PETER NORMAN —
KRISTI THOMPSON —

Contacted: Veterans Affairs, Dept of (VA); Natl Institutes of Health (NIH); Executive Office of the President (EOP); Substance Abuse & Mental Health Services Administration (SAMHSA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Office of Natl Drug Control Policy (NDCP); Justice, Dept of (DOJ); SENATE

Bills named: H.R. 5909 (116th), S. 2690 (116th), S. 3312 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.